Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 16;13(8):e031578.
doi: 10.1161/JAHA.123.031578. Epub 2024 Apr 2.

Cost-Effectiveness of a Workplace-Based Hypertension Management Program in Real-World Practice in the Kailuan Study

Yan-Feng Zhou  1 , Shuohua Chen  2 , Jun-Xiang Chen  3 , Simiao Chen  4   5 , Guodong Wang  2 , Xiong-Fei Pan  6 , Shouling Wu  2 , An Pan  3
Affiliations

Cost-Effectiveness of a Workplace-Based Hypertension Management Program in Real-World Practice in the Kailuan Study

Yan-Feng Zhou et al. J Am Heart Assoc. .

Abstract

Background: In 2009, a workplace-based hypertension management program was launched among men with hypertension in the Kailuan study. This program involved monitoring blood pressure semimonthly, providing free antihypertensive medications, and offering personalized health consultations. However, the cost-effectiveness of this program remains unclear.

Methods and results: This analysis included 12 240 participants, with 6120 in each of the management and control groups. Using a microsimulation model derived from 10-year follow-up data, we estimated costs, quality-adjusted life years (QALYs), life-years, and incremental cost-effectiveness ratios (ICERs) for workplace-based management compared with routine care in both the study period and over a lifetime. Analyses are conducted from the societal perspective. Over the 10-year follow-up, patients in the management group experienced an average gain of 0.06 QALYs with associated incremental costs of $633.17 (4366.85 RMB). Projecting over a lifetime, the management group was estimated to increase by 0.88 QALYs or 0.92 life-years compared with the control group, with an incremental cost of $1638.64 (11 301.37 RMB). This results in an incremental cost-effectiveness ratio of $1855.47 per QALY gained and $1780.27 per life-year gained, respectively, when comparing workplace-based management with routine care. In probabilistic sensitivity analyses, with a threshold willingness-to-pay of $30 765 per QALY (3 times 2019 gross domestic product per capita), the management group showed a 100% likelihood of being cost-effective in 10 000 samples.

Conclusions: Workplace-based management, compared with routine care for Chinese men with hypertension, could be cost-effective both during the study period and over a lifetime, and might be considered in working populations in China and elsewhere.

Keywords: blood pressure; economic evaluation; health consultation; hypertension; workplace‐based.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Markov state transition model for hypertension.
MI indicates myocardial infarction.
Figure 2
Figure 2. Cost‐effectiveness acceptability curve and incremental cost‐effectiveness scatter plots of the workplace‐based, multicomponent hypertension management program.
A, Cost‐effectiveness acceptability curve. B, Incremental cost‐effectiveness scatter plots: WTP, $30 765/QALY (3× GDP per capita/QALY). GDP indicates gross domestic product; QALY, quality‐adjusted life year; and WTP, willingness‐to‐pay.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. GBD 2019 risk factors collaborators . Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396:1223–1249. doi: 10.1016/S0140-6736(20)30752-2 - DOI - PMC - PubMed
    1. Sudharsanan N, Theilmann M, Kirschbaum TK, Manne‐Goehler J, Azadnajafabad S, Bovet P, Chen S, Damasceno A, De Neve JW, Dorobantu M, et al. Variation in the proportion of adults in need of blood pressure‐lowering medications by hypertension care guideline in low‐ and middle‐income countries: a cross‐sectional study of 1037215 individuals from 50 nationally representative surveys. Circulation. 2021;143:991–1001. doi: 10.1161/CIRCULATIONAHA.120.051620 - DOI - PMC - PubMed
    1. Geldsetzer P, Manne‐Goehler J, Marcus ME, Ebert C, Zhumadilov Z, Wesseh CS, Tsabedze L, Supiyev A, Sturua L, Bahendeka SK, et al. The state of hypertension care in 44 low‐income and middle‐income countries: a cross‐sectional study of nationally representative individual‐level data from 1.1 million adults. Lancet. 2019;394:652–662. doi: 10.1016/S0140-6736(19)30955-9 - DOI - PubMed
    1. Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, Cheng X, Mu L, Zhang H, Liu J, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population‐based screening study (China PEACE million persons project). Lancet. 2017;390:2549–2558. doi: 10.1016/S0140-6736(17)32478-9 - DOI - PubMed
    1. Zhou YF, Chen S, Wang G, Chen S, Zhang YB, Chen JX, Tu ZZ, Liu G, Wu S, Pan A. Effectiveness of a workplace‐based, multicomponent hypertension management program in real‐world practice: a propensity‐matched analysis. Hypertension. 2022;79:230–240. doi: 10.1161/HYPERTENSIONAHA.121.18305 - DOI - PubMed

Substances

LinkOut - more resources